Hemostatic agent; has also an angioprotective and proaggregant effect. Stimulates the formation of platelets and their exit from the bone marrow. Hemostatic action due to activation of thromboplastin formation at the site of small vessel damage and decreased formation of prostacyclin vessels in the endothelium (PgI2), promotes an increase in adhesion and aggregation of platelets, which ultimately leads to stopping or reducing bleeding. Increases the rate of formation of the primary thrombus and enhances its retraction, practically does not affect the concentration of fibrinogen and prothrombin time. Doses of more than 2-10 mg / kg do not lead to greater severity of the effect. With repeated injections, thrombus formation is intensified.
Possessing anti-hyaluronidase activity and stabilizing ascorbic acid, it prevents destruction and promotes the formation in the capillary wall of mucopolysaccharides with a large molecular weight, increases the resistance of capillaries, reduces their fragility; normalizes permeability in pathological processes.
Reduces the yield of fluid and diapedesis of blood elements from the vascular bed, improves microcirculation.
Does not have hypercoagulable properties. Does not have vasoconstrictive action.
Recovers pathologically altered bleeding time. The hemostasis does not influence the normal parameters of the system.
Hemostatic effect with intravenous (iv) introduction of etamzilate occurs in 5-15 minutes, the maximum effect is manifested in 1-2 hours. The effect lasts for 4-6 hours, then within 24 hours gradually weakens; with intramuscular (in / m) introduction, the effect comes somewhat slower.
After the course treatment, the effect persists for 5-8 days, gradually weakening.